Phosphocysteamine
Title: Phosphocysteamine
CAS Registry Number: 5746-40-7
CAS Name: 2-Aminoethanethiol dihydrogen phosphate (ester)
Additional Names: phosphorothioic acid S-(2-aminoethyl) ester; cysteamine-S-phosphate; MEAP
Molecular Formula: C2H8NO3PS
Molecular Weight: 157.13
Percent Composition: C 15.29%, H 5.13%, N 8.91%, O 30.55%, P 19.71%, S 20.41%
Line Formula: H2NCH2CH2SPO3H2
Literature References: Radioprotectant. Prepn of sodium salt: S. Åkerfeldt, Acta Chem. Scand. 13, 1479 (1959); of free acid: idem, ibid. 14, 1980 (1960). Radioprotective effect: B. Hansen, B. Sörbo, Acta Radiol. 56, 141 (1961); A. Vacek et al., Folia Biol. (Prague) 17, 340 (1971). Mechanism of action: B. Shapiro et al., Radiat. Res. 44, 421 (1970). Radiobiological and biochemical profile: J. W. Harris, T. L. Phillips, ibid. 46, 362 (1971). Photoreactivity: S. A. Grachev et al., Radiochem. Radioanal. Lett. 19, 283 (1974); H. Neumann, M. Sokolovsky, Biochim. Biophys. Acta 381, 292 (1975). Clinical evaluation in cystinosis: L. A. Smolin et al., Pediatr. Res. 23, 616 (1988); D. S. Theodoropoulos et al., J. Am. Med. Assoc. 270, 2200 (1993).
Properties: Crystals from glacial acetic acid, mp 156°. pKa: 2.2, 5.0, 10.3.
Melting point: mp 156°
pKa: pKa: 2.2, 5.0, 10.3
 
Derivative Type: Sodium salt
CAS Registry Number: 3724-89-8
Additional Names: Sodium hydrogen-S-(2-aminoethyl)phosphorothioate; cystafos; cystaphos
Manufacturers' Codes: WR-638
Molecular Formula: C2H7NNaO3PS
Molecular Weight: 179.11
Percent Composition: C 13.41%, H 3.94%, N 7.82%, Na 12.84%, O 26.80%, P 17.29%, S 17.90%
Properties: White crystalline water soluble powder. LD50 i.p. in male mice: 0.93 ±0.03 g/kg (Hansen).
Toxicity data: LD50 i.p. in male mice: 0.93 ±0.03 g/kg (Hansen)
 
Use: Research radioprotective agent.
Therap-Cat: Treatment of cystinosis.

Others monographs:
Silver CyanideDoxifluridine4-Methylbenzylidene CamphorAlkofanone
ThymostatinProflavineAltheaDIDS
RosaprostolSiduronTriacetone TriperoxideAzaconazole
o-ChlorobenzylidenemalononitrileItramin TosylateViquidilSorafenib
©2016 DrugLead US FDA&EMEA